⌘K
A
Aisling Capital
Deals on record
1
Common Fundraising Type
Series C
B
Bicara Therapeutics
Biotechnology • Clinical-stage
Bicara Therapeutics is a clinical-stage biotech company focused on developing BCA101, a novel bifunctional inhibitor targeting EGFR and TGF-β pathways for the treatment of various cancers.